5 ms·
The amount of innovation and capital at risk in private biotech companies is similar to that for the tech industry. If we got rid of the tech industry and had
by refurb 8y ago
The amount of innovation and capital at risk in private biotech companies is similar to that for the tech industry.
If we got rid of the tech industry and had the govt do all of it, do you believe we’d be where we are today?
I’d argue we wouldn’t be.
One of the big reasons why small biotech’s outperform big pharmaceutical companies is the lack of bureaucracy and high level of risk taking. Two things the govt is bad at.
As well, one reason why we have so many drugs is there are thousands of companies placing different bets on an idea. If that was all pulled under a centralized committee that made decisions on what to pursue, we’d be missing out on a ton of long-shots that every “smart” person said would never work.
- ace_of_spades 8y agoThank you for your opinion! :) You make it sound like there is a hard barrier between these two options but like most things in reality it is a continuum. You can have mainstream R&D be publicly funded all the way and not necessarily restrict private companies from competing. I personally believe that there is a good chance that a centralized publicly funded and nonprofit pharmaceutical organization could outperform most for profits on various important metrics. At least something that should be investigated and not dismissed outright. Regarding long-shots, I think you fall victim to the survivorship bias here. Even if some good things came out of it, the question is at what cost? If many tries fail you really need some big wins to cover those costs. Thus, it’s really something that you should look into on an empirical level before making strong judgements.
- aaavl2821 8y agoOut of curiosity, do you have any specific proposals thoughts about what this centrally funded / non profit approach would look like, and why it would work? My contention is that drugs are expensive because developing drugs is expensive. Developing drugs is expensive because biology is hard. Public vs private funding would not change that
- ace_of_spades 8y agoHey, sorry for getting back to you so late but I had a full weekend :) I am not an expert in the pharmaceutical space so take everything I say with a big grain of salt. I would think it could be possible to have some agency like NSF or FDA be tasked with financing studies to develop medicines and do medical trials, etc. I don’t think it would need to look much different what there is now, maybe higher and more long-term grants for applied R&D. Manufacturing could then be outsourced, Apple style. I guess the main challenge would be to have reporting and grants be distributed effectively and fairly. There should be some level of friendly competition/ cooperation to ensure that progress is being made. But I think, in principle this already works pretty well through peer review and on some level metric tracking for individual researchers (although I would argue we still often track the wrong metrics). So it’s all about designing the right incentives work work to get done, profit is but one of the possible metrics to achieve that. This of course does not change that the work itself is incredibly hard. The benefit of doing it in a more „structured“ and nonprofit way is that it is possible to create a more specific/ tailored/ guided set of outcomes given the ability to align the incentives with societal goals. Everything you see going on in blockchain is work in that direction. How can we design economic systems where incentives are aligned to create an overall desireable outcome for individuals, the community and society at large?
- qubex 8y agoThe notion ghat “the government” is ‘bad’ at spurring innovation in high-risk scenarios is both common and flawed. It was NASA that sent men to the moon and, more pertinently, it was ARPA that shouldered the risks upon which the predecessor of the Internet (and packet-routing networks generally) was built, as well as (to a lesser degree) the microprocessor. I’m not quite sure why this is such a persistent impression, parroted by folks who, if they thought it through properly themselves, would reach the opposite (correct) conclusion.
- aaavl2821 8y agoI think the concern is not that the government can't spur r&d, but publicly funded r&d would be less efficient than private capital Back in the 1960s no other organization but the government had enough money to fund something as ambitious as the space program. And the government spends a ton of defense research and always has. Sheer volume of capital can get things done, but that doesn't mean it is efficient The belief is that private markets incentives more efficient research than public funding. So if there is enough private capital to support some r&d goal, it is preferred to fund it privately vs publicly I'm sure there's research on this but as someone who has worked on r&d at small companies, large companies and with government funded grants, there's little doubt in my mind what groups are more efficient. If you look at r&d productivity at big pharma companies vs small, small companies are almost an order of magnitude better. And out of 47 new drugs approved last year, 40% were developed by small companies, 30-35% by big companies, and 1 from a public private partnership (the rest were mid sized companies). That's despite small companies getting an order of magnitude less funding than big ones, and half as much funding as NIH
- philipkglass 8y agoDoes that 40% figure refer to taking drugs all the way through clinical trials and FDA approval, or does it also include e.g. drugs that small companies brought through earlier stages of the pipeline before well-capitalized BigCorp acquired/partnered to finish approval? My impression is that drug development costs are heavily weighted toward the later phase clinical trials, and that it’s rare for a startup to complete them without help/acquisition from one of the big incumbents. I could be wrong about this. My lay perspective is that of someone who used to be a (non-pharma) chemist and who enjoys reading Derek Lowe. But if I’m right, and small companies usually can’t finish fully independently, that suggests a role for government drug development: funding the clinical trials and completing approval. Whether a government agency or GSK provides that funding doesn’t seem to much affect innovation of small companies in earlier stages.
- prolikewh0a 8y ago>If we got rid of the tech industry and had the govt do all of it, do you believe we’d be where we are today? Aren't a lot of core inventions/breakthroughs in most of our current technology (at least in USA) made by Military? https://www.businessinsider.com/the-us-military-is-responsible-for-almost-all-the-technology-in-your-iphone-2014-10 https://www.businessinsider.com/the-us-military-is-responsib...
- aaavl2821 8y agoThe centralized model you refer to in the last paragraph is akin to how a lot of big pharma r&d groups work. And they get about 10x less innovation per dollar spent than small companies (innovation measured as drugs approved) Imagine how much worse that would be if it was govt rather than a big company